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Abstract The high mobility group (HMG) I proteins are small,
non-histone chromosomal proteins that promote gene activation
during development and within rapidly dividing cells. They do so
by facilitating enhanceosome formation on inducible genes, via
both protein/DNA and protein/protein interactions. The HMG I-
C gene is tightly regulated, normally being expressed exclusively
during embryonic development. However, HMG I-C expression
is also observed frequently in a number of tumor types, and this
expression has been shown to contribute to the malignant
transformation process. With the aim of dissecting pathways that
lead to aberrant expression of HMG I-C in tumor cells, we have
analyzed HMG I-C gene regulation in the human hepatoma cell
line PLC/PRF/5. One of the two HMG I-C transcripts detected
in this cell line originates from a novel downstream initiation site
at nucleotide 3161 relative to the first methionine. Transcription
from the downstream initiation site is mediated by a PRE located
between nt 3222 and 3217. We show here that the Sp1 and Sp3
transcription factors interact with the PRE and transactivate the
HMG I-C promoter in a cooperative fashion. This study provides
the first characterization of this downstream HMG I-C
promoter.
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1. Introduction
High mobility group (HMG) I proteins are non-histone,
chromatin-associated proteins that participate in nucleosomal
assembly and the transcriptional regulation of RNA polymer-
ase II genes [1^4]. The HMG I, Y and I-C proteins are re-
ferred to collectively as ‘architectural’ factors, as they have
few or no direct transcription regulatory properties, but play
critical roles in enhanceosome formation [5^7]. Unlike the
similarly named, yet structurally distinct HMG proteins (con-
taining an HMG box), the HMG I proteins interact with the
minor groove of AT-rich DNA using three tandem DNA
binding domains (also called AT hooks), located in the central
portion of the polypeptides [8,9]. Via these interactions with
DNA and with traditional transcription factors (e.g. Oct2,
ATF-2, and NF-UB), the HMG I proteins have been shown
to be critical for the generation of a higher order, multi-pro-
tein transcription complex on a variety of promoters (e.g.
interferon-L, HLA-DRA and E-selectin) [10,11]. In addition,
HMG I binding to DNA is also known to either bend DNA
or reverse intrinsic bends, which has also been shown to pro-
mote the interaction of certain factors with their DNA recog-
nition sequence [12].
An important role for HMG I proteins in transcriptional
regulation was ¢rst shown with inducible genes whose gene
products participate in the immune response [13]. One exam-
ple involves the interferon-L gene, the expression of which is
activated by viral infection [14]. In this case, HMG I(Y) pro-
teins operate by reversing intrinsic bends within the promoter
and by facilitating the interaction of ATF-2 and NF-UB with
DNA and with each other [12,3]. A second example involves
the human class II major histocompatibility complex (MHC)
gene, HLA-DRA [15,16]. In this system, HMG I(Y) proteins
interact with six discrete sites within the HLA-DRA proximal
promoter. Interaction of the protein with three of these sites:
the TATA box, the octamer element and AT-rich stretch be-
tween the consensus X and Y boxes, has been shown to be
essential for induction of HLA-DRA gene expression by in-
terferon-Q. In the case of the TATA box and the octamer
element, HMG I(Y) contributes to gene activation by facili-
tating the loading of TBP or Oct-2A on these sites, respec-
tively [15]. Interaction of HMG I(Y) with the ‘interspace’
element found between the X and Y boxes appears to con-
tribute to induction of the gene by bending DNA and facili-
tating protein/protein interactions between X box and Y box
binding factors. Finally, the HMG I-C protein appears to be
important for the activation of the MuRantes promoter by
viral infection, and has been shown to have very similar en-
hanceosome-promoting activities to HMG I(Y) [17].
The HMG I-C gene is expressed at high levels during em-
bryonic development and is subsequently completely repressed
in adult tissues [18,19]. Expression of the HMG I-C gene is
reactivated in many tumors, and evidence now suggests that
HMG I-C gene expression may contribute to cellular trans-
formation [20]. Support for the hypothesis that HMG I-C
gene expression is important for cellular growth comes from
the ¢nding that disruption of the HMG I-C gene results in a
runted or ‘pygmy’ mouse with a speci¢c blockade in adipo-
genesis [21]. In addition, the expression of antisense HMG I-C
RNA e¡ectively prevents neoplastic transformation of rat thy-
roid cells by retroviral oncogenes [22]. Most recently, this has
been shown to operate through the induction of junB and fra-
1, since inhibition of HMG I-C downregulates the expression
of these factors, and since inhibition of these factors directly
a¡ects tumorigenicity [23]. Finally, the groups of Van de Ven
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and Chada have made the remarkable ¢nding that transloca-
tions frequently occur within the HMG I-C gene in a variety
of benign mesenchymal tumors [24,25]. These translocations
usually occur between exons 3 and 4 to either truncate the
HMG I-C protein at the C-terminus of the third AT hook or
to attach a heterologous coding sequence after the DNA bind-
ing domain to create a novel fusion protein. Thus, either the
derepression of HMG I-C gene expression or the production
of a truncated or fusion polypeptide may result in the activa-
tion of growth control genes and the dedi¡erentiation of ter-
minally di¡erentiated cells into rapidly growing cells which are
destined to become benign or metastatic tumors [26].
With the aim of dissecting molecular mechanisms leading to
HMG I-C gene expression in tumor cells, we have character-
ized the proximal promoter of the human gene in the context
of the hepatoma cell line PLC/PRF/C [27]. This line has been
previously shown to express high levels of HMG I-C tran-
scripts. In this article, we report the identi¢cation of a novel
downstream transcription initiation site and the characteriza-
tion of its associated promoter. Mutagenesis of this down-
stream promoter indicates that an evolutionarily conserved
repetitive sequence upstream of the start site acts as a major
positive regulatory element, and binds the Sp1 and Sp3 tran-
scription factors. Finally, transient transfection studies in
SL-2 cells indicate that Sp1 and Sp3 can cooperate in the
activation of this promoter.
2. Materials and methods
2.1. Sequence analysis
The entire nucleotide sequence of the human HMG I-C gene in the
region discussed in this paper has been previously published by one of
us [27]. Selected regions of the human HMG I-C gene 5P untranslated
region (UTR) were scanned for known cis-elements using the SIGS-
CAN v4.05 program at http://bimas.dcrt.nih.gov/molbio/signal [28].
2.2. Cell culture
Human hepatoma cells PLC/PRF/C and non-malignant human
mammary epithelial cells HBL100 (from Marc E. Lippman, Lombardi
Cancer Center, Georgetown University) were maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 2 mM GlutaMaxI and antibiotics. Schneider’s Droso-
phila melanogaster cells SL-2 (purchased from ATCC) were cultured
at 25‡C in Schneider’s Drosophila Medium supplemented with 10%
fetal bovine serum and antibiotics. All reagents for cell culture were
obtained from Gibco BRL (Gaithersburg, MD). HBL100 is a mam-
mary line established in vitro from milk of an apparently healthy
woman [29].
2.3. RNA analysis
Total RNA was prepared from exponentially growing cells using
the acid phenol method [30]. For Northern blot analysis, RNA was
electrophoresed in 1.5% formaldehyde-denaturing agarose gel, with
the 0.24^9.5 kb RNA Ladder included in one lane as a size marker
(Gibco BRL, Gaithersburg, MD). RNA was then transferred onto
Biodyne B membrane (Pall, East Hills, NY) according to manufac-
turer’s recommendations and ¢xed. The human HMG I-C gene-cod-
ing region was used as probe labeled with [K-32P]dCTP (ICN, Costa
Mesa, CA) by random priming using the RediPrime DNA Labeling
Kit (Amersham, Arlington Heights, IL) and puri¢ed by NucTrap
Push Columns (Stratagene, La Jolla, CA). Hybridization was carried
out in QuikHyb Hybridization Solution (Stratagene) at 68‡C with
40 Wg/ml sonicated salmon sperm DNA (Sigma, St. Louis, MO) and
typically 10 ng/ml probe. The blot was stringently washed with
0.1USSC, 0.1% SDS at 68‡C for 15 min twice. Autoradiography
was performed using Fuji Rx ¢lm with intensifying screen (Sigma,
St. Louis, MO) at 370‡C. The same blot was stripped after probing
and then reprobed with the 32P-labeled 28S rRNA probe to control
for equivalent RNA loading in each lane.
2.4. Primer extension analysis
The oligonucleotide: 5P-GGAGATGAGGTGATAGGGCTGGG-
G-3P (spanning nt 375 to 398, Fig. 3C) (obtained from Genosys,
Woodlands, TX) was end-labeled with [Q-32P]ATP (ICN, Costa
Mesa, CA) and T4 Polynucleotide Kinase (New England Biolabs,
Beverly, MA) and then gel puri¢ed on a 13.3% polyacrylamide/
1UTBE gel. 30 000 cpm of oligonucleotide was subsequently mixed
with 20 Wg of total RNA in 30 Wl of hybridization solution (66%
deionized formamide, 20 mM Tris-HCl, pH 7.4, 400 mM NaCl,
0.1% SDS and 1 mM EDTA) and heated at 85‡C for 10 min. The
solution was then incubated at 55‡C for 8^12 h. The RNA and an-
nealed primer were then ethanol precipitated, washed, vacuum dried
and resuspended in 20 Wl of reaction solution which contained 1Ure-
verse transcriptase bu¡er, 0.5 mM of dNTPs, 20 units of RNasin
ribonuclease inhibitor (Promega, Madison, WI) and 200 units of
SuperScript II RNase H3 Reverse Transcriptase (Gibco BRL, Gai-
thersburg, MD). The extension reaction was carried out at 42‡C for
50 min and then stopped by adding EDTA to a ¢nal concentration of
25 mM. 10 Wg of sonicated salmon sperm DNA and 2 Wg of DNase-
free RNase A (Sigma, St. Louis, MO) were added and incubated at
37‡C for 30 min. The extension products were then puri¢ed with
phenol/chloroform extraction, ethanol precipitated, washed, dried, re-
suspended in 2 Wl of dH2O and 2 Wl of sequencing gel loading dye.
Samples were heated at 90‡C for 2 min, then electrophoresed through
8% denaturing polyacrylamide (sequencing) gels. A sequencing ladder
generated using the same oligonucleotide primer served as a marker.
Autoradiography was performed to visualize the extension products.
2.5. Plasmid construction
Luciferase reporter plasmids were constructed by subcloning ge-
nomic fragments of the human HMG I-C gene 5P UTR [31] into
pGL2-Basic Luciferase Reporter Vector (Promega, Madison, WI).
The remaining 5P deletion constructs were prepared by nested deletion
using the ExoIII/S1 deletion kit (MBI Fermentas, Amherst, NY). The
orientation and nucleotide sequence of each construct were veri¢ed
by DNA sequencing using Sequenase v.2 DNA Sequencing Kit
(Amersham, Arlington Heights, IL). All restriction and modifying
enzymes unless stated were obtained from New England Biolabs
(Beverly, MA). Site-directed mutagenesis was conducted using the
U.S.E. Mutagenesis Kit (Pharmacia Biotech, Piscataway, NJ) accord-
ing to the manufacturer’s protocol. An oligonucleotide carrying
mismatched bases (underlined nucleotides): 5P-CCGCCACCGGCA-
GCGCCTGATCGATTCAAGGTAGTCCTCCCCTCTTCTCTTTT-
TGG-3P was used to mutagenize nt 3232 to 3217 of the segment of
the I-C gene promoter spanning from nt 3289 to 331 of the luciferase
reporter plasmid (Fig. 3C). Expression plasmids for Sp1 and Sp3 were
kindly provided by Dr. Jonathan M. Horowitz at North Carolina
State University.
2.6. Transfections, luciferase and L-galactosidase enzyme assays, and
protein concentration
Plasmid DNA for transfection was prepared by Qiagen Plasmid kit
(Chatsworth, CA). PLC/PRF/5 cells were seeded in 35 mm plates,
grown for 20 h until they were 40% con£uent. For each transfection,
2.5 Wg of pGL2 (luciferase expression vector, Promega, Madison, WI)
and 2.5 Wg of each pCH110 Eukaryotic Assay Vector (served as an
internal control to determine transfection e⁄ciency by monitoring L-
galactosidase expression, Pharmacia Biotech, Piscataway, NJ) were
added to each transfection reaction using 15 Wg of LipofectAMINE
reagent according to the manufacturer’s recommended procedures
(Gibco BRL, Gaithersburg, MD). After 6 h cells were transferred to
DMEM supplemented with 20% fetal calf serum and incubated for an
additional 44 h at 30‡C. Transfections were carried out in duplicate
and repeated at least three times. Transfection of Drosophila SL-2
cells was performed using 6 Wg of CellFectin reagent (Gibco BRL),
and 1 Wg of the luciferase reporter plasmid and 0.5 Wg of the Sp1 or
Sp3 expression plasmid. Cells were seeded in 35 mm plates to 40%
con£uence prior to transfection, and after 2 days cells were harvested.
For luciferase and L-galactosidase enzyme assays, the transfected
cells were washed 2 times with PBS and then lysed in 150 Wl of
1Ureporter lysis bu¡er (Promega, Madison, WI). The cell lysates
were harvested, frozen and thawed, and then spun. The supernatants
were collected for use in luciferase and L-galactosidase assays. For
luciferase analysis, 30 Wl of the transfected cell extracts were mixed
with 50 Wl of room temperature equilibrated Luciferase Assay Re-
agent as indicated in protocols supplied by the manufacturer (Prom-
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ega, Madison, WI). Luciferase activity was measured using a Mono-
light 2010 luminometer (Analytical Luminescence Laboratory, San
Diego, CA). Light output was integrated over a 20 s period and
displayed as relative light units (RLU). Background activity was
found to be less than 0.1% of all readings. For L-galactosidase activ-
ity, the L-Galactosidase Enzyme Assay System was used following the
instruction manual from the manufacturer (Promega, Madison, WI).
All L-galactosidase activities were within the linear range of the ab-
sorbance curve. Protein concentration of cell lysates was assayed by
BCA Protein Assay kit (Pierce, Rockford, IL).
2.7. Preparation of nuclear extracts
Nuclear extracts from PLC/PRF/C cells were prepared as follows:
about 1U106 cells were harvested, washed twice with cold PBS and
collected by centrifugation at 3500 rpm at 4‡C for 5 min. The cells
were resuspended in 400 Wl of solution I (10 mM HEPES, pH 7.9,
10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.1 mM DTT, 0.5 mM
PMSF) and lysed by passing them through a 25 gauge syringe. Nuclei
were pelleted at 2000 rpm for 10 min, washed once with solution I
and resuspended in 200 Wl of solution II (solution I with 5% glycerol,
400 mM NaCl and without KCl). The suspension was rotated at
4‡C for 30 min and then centrifuged at 14 000 rpm, 4‡C, for
30 min. The resulting clear supernatant was stored at 380‡C until
use.
2.8. Electrophoretic mobility shift assay (EMSA) and
supershift assay
A 20 bp long oligonucleotide 5P-CTCCTCCTCTCCTCCTCCTC-3P
(oligo A) extending from nt 3234 to 3215 on the 5P UTR of HMG I-
C gene, and its point-mutated version 5P-CTGATCGATTCAAGG-
TAGTC-3P (m-oligo A) (Fig. 3C) were used in EMSA and supershift
assay. Double stranded DNA fragments were end-labeled with
[Q-32P]ATP (ICN, Costa Mesa, CA) and T4 polynucleotide kinase
(New England Biolabs, Beverly, MA). The probes were gel puri¢ed
and 15 000 cpm were incubated for 25 min at room temperature with
4 Wg of nuclear extract from PLC/PRF/C cell line, in the presence of
20 mM Tris-HCl pH 7.5, 75 mM KCl, 3.5 mM DTT, 20 nM ZnCl2,
1 Wg/Wl BSA, 5% glycerol and 1 Wg poly(dI-dC) (Pharmacia Biotech,
Piscataway, NJ) in a ¢nal volume of 20 Wl. For supershift experi-
ments, 1 Wg of antibody against Sp1, Sp3 or NF-UB p65 (Santa
Cruz Biotechnology, Santa Cruz, CA) was incubated for 20 min at
room temperature with the nuclear extract before adding the labeled
probe. DNA/protein complexes were separated from free DNA on a
5% polyacrylamide gel in TBE (89 mM Tris, 89 mM boric acid, 2 mM
EDTA) at 4‡C for 120 min at 100 V. After electrophoresis, gels were
dried and autoradiographed.
3. Results
3.1. Two species of HMG I-C mRNA are detected in the
PLC/PRF/5 hepatoma cell line
The human HMG I-C cDNA was cloned previously from
the PLC/PRF/5 hepatoma cell line [27], as it expresses ex-
tremely high levels of HMG I-C transcript. We have therefore
chosen to dissect molecular mechanisms driving HMG I-C
gene expression in this tumor cell line. Previous Northern
blot analyses of RNAs isolated from this cell line, as well as
from the human colorectal adenocarcinoma cell line DLD-1
and 15.5 dpc mouse embryos, detected a single transcript of
approximately 4.1 kilobases [32]. These RNAs were resolved
on low percentage (up to 1.2%) agarose gels. We have sub-
sequently resolved a second, smaller transcript of 3.8 kb in
Fig. 1. Northern blot analysis of the hepatoma cells PLC/PRF/5,
showing the presence of two HMG I-C transcript species. Total
RNA (20 Wg) isolated from human hepatoma cells PLC/PRF/5 (lane
1) and normal breast cell line HBL100 (lane 2) was resolved onto
1.5% denaturing gel and transferred to nylon membrane. The blot
was hybridized with 32P-labeled human HMG I-C coding region
(top panel) and then 28S rRNA probe (bottom panel). The sizes of
the two I-C transcripts are indicated.
Fig. 2. Mapping of the HMG I-C gene promoters in the PLC/PRF/5 hepatoma cell line. Cells were transiently transfected using liposomes with
constructs spanning di¡erent regions of the I-C gene 5P UTR fused to luciferase reporter (diagram on the left). We number the nucleotide be-
ginning immediately upstream from the ¢rst methionine ATG as +1, and the construct numbering parallels the position of the upstream region
of I-C gene with respect to the upstream sequence from the translation start site. A promoter-less reporter plasmid was also transfected for
negative control. Another SV40-driven L-galactosidase control plasmid was included in all transfection experiments. Luciferase activity was pre-
sented after normalization to L-galactosidase activity. The graph on the right shows the mean þ S.E.M. of at least three transfections with two
independent batches of DNA.
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Fig. 3. Characterization of the downstream HMG I-C promoter (nt 3473 to 331). A: Deletion analysis of the fragment by transfecting a 5P
deletion series of the fragment into PLC/PRF/5 cells. Data are a summary of at least three transfections from two independent plasmid prepa-
ration. The mean values and standard errors are shown. The PRE was demonstrated at nt 3222 to 3217, since deletion of this region reduced
3-fold the promoter activity of the preceding deletant. B: Primer extension analysis of the downstream promoter. Primer extension of 20 Wg of
total RNA prepared from PLC/PRF/5 (lane 1) and HBL100 (lane 2) was performed with 32P-end-labeled oligonucleotide complementary to the
human I-C gene region nt 375 to 398 (relative to ATG) as described in the text. Primer extension products were analyzed onto a denaturing
polyacrylamide gel, and size of the extended product were deduced from adjacent dideoxy-sequencing ladder. The Davidic star to the left of
the sequence indicates the transcription start site (at nt 3161). Experiments were repeated twice. C: Nucleotide sequence of the downstream
HMG I-C gene promoter region. The nucleotide sequence is numbered in a way where +1 corresponds to the A of the initiator methionine co-
don, and residues preceding it are represented by negative numbers. The ¢rst nucleotide in each row is numbered on the left hand side, the
number of the last nucleotide is indicated on the right hand side. Consensus transcription factor recognition sites are shown, among them Sp1/
Sp3 binding sites are identi¢ed in the PRE (nt 3222 to 3217). Underlined is the sequence for gel-shift analysis, the bottom of which shown in
gray represents the mutated sequence. The arrow depicts the location of the oligonucleotide annealed for primer extension. The bent arrow in-
dicates the mapped transcriptional start site. Restriction sites are underlined. The methionine start codon is in upper case. D: EMSA and
supershift analysis of region between nt 3234 and nt 3215 on the HMG I-C promoter. F, free probe; 3, Sp1 and Sp3 show the result of
band shift analysis in the absence or presence of antibody against Sp1 and Sp3 respectively. OLIGO A and m-OLIGO A are wild-type and
point-mutated oligonucleotides as described in Section 2. The Sp1 supershifted complex is indicated by a double arrow.
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Northern blots of RNAs resolved on 1.5% denaturing agarose
gels (Fig. 1). The smaller transcript is present at levels that are
approximately 50% of the longer transcript. No HMG I-C
transcripts were detected in the normal breast cell line
HBL100. We therefore used this line as a negative control
in subsequent experiments.
The existence of two forms of HMG I-C transcript in this
cell line could be due to two distinct transcription initiation
sites, two distinct transcription termination sites, and/or alter-
native splicing or processing of precursor RNAs. We ruled
out the possibility that transcription was terminating at two
sites, by performing multiple Northern blots using a series of
DNA probes located downstream of the terminal HMG I-C
exon (data not shown). We were unable to obtain selective
hybridization to either the 4.6 or 3.8 kb band using any of the
probes, strongly suggesting that termination occurs at either a
single site, or in a restricted region. These data are in agree-
ment with the data from the Chada and Van de Ven groups,
and suggests that transcription terminates downstream of the
second and third polyadenylation signals AAUAAA, produc-
ing a 3P UTR of length about 3 kb [24,25]. In addition, it is
highly unlikely that the two transcripts are due to alternative
splicing within the coding region, as 0/10 cDNA clones iso-
lated from a PLC/PRF/5 library, had internal deletions of any
exon ([27], K.-Y. Chau, U.A. Patel and C. Crane-Robinson,
unpublished observations).
3.2. Identi¢cation of two upstream HMG I-C fragments with
maximal promoter activity in the PLC/PRE/5 hepatoma
cell line
Several cDNAs were isolated from a library of PLC/PRF/5
hepatoma cell line and their 5P termini mapped. The 5P UTRs
of all HMG I-C cDNAs cloned to date were less than 1 kb.
Approximately half of the cloned cDNAs isolated from this
cell line had a 5P terminus approximately 800 bp upstream,
and the other half cluster at less than 400 bp upstream of the
¢rst translational start codon. We therefore had a priori evi-
dence that transcripts from this gene might initiate from two
transcription initiation sites, and thus two promoters. We
therefore generated a series of luciferase reporter constructs
containing overlapping fragments within the proximal 3 kb
upstream of the ¢rst ATG. These and several other reporter
constructs were transfected into the PLC/PRF/5 hepatoma
cell line, and promoter activities assessed (data not shown).
Only two of the genomic fragments, one (spanning nt 31125
to 3868) and the other (spanning nt 3473 to 331) had strong
promoter activity (Fig. 2). We therefore reasoned that both
transcription initiation sites and positive regulatory elements
driving HMG I-C gene expression in these cells would map
within these fragments.
3.3. Analysis of the downstream promoter fragment (nt 3473
to 331) and localization of its transcription initiation site
Since the downstream promoter fragment was unique to
previous work in the literature (the upstream promoter has
been previously described [32]), we focused our e¡orts on
characterizing the downstream promoter. Unfortunately,
there were no convenient restriction enzyme sites within the
downstream fragment that could be used to generate the re-
quired progressive deletions at this location. Exonuclease III
was therefore used to make progressive 5P deletions, of which
a fraction is shown in Fig. 3A. Truncations from nt 3473 to
Fig. 3 (continued).
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3222 had little e¡ect on promoter activities within the PLC/
PRF/5 cell line. However, deletion to nt 3217, and all further
deletions resulted in a dramatic decrease in promoter activity.
We interpreted these data to indicate that either a critical
positive regulatory element (PRE), or a transcription initia-
tion site is located near nt 3222 and 3217. We therefore
mapped the region surrounding these nucleotides for tran-
scription initiation site(s). Although several spurious extension
products were observed in RNAs extracted from both the
PLC/PRF/5 and HBL100 cell lines (Fig. 3B, lanes 1 and 2),
we reproducibly observed one unique extension product in
RNAs from the PLC/PRF/5 cell line corresponding to a
downstream transcription initiation site (Fig. 3B, lane 1).
The sequence of this region and the position of the start site
are shown in Fig. 3C. The location of the primer binding site
is also shown as a bold antiparallel arrow. As was the case
with the upstream start, no TATA boxes are found near this
site.
3.4. Sp1 and Sp3 DNA binding proteins interact with the
downstream HMG I-C PRE in a sequence-speci¢c manner
We inspected the nucleotide sequences within the down-
stream PRE for known cis-elements. Analysis of the down-
stream PRE £anking sequence between nt 3473 and 3161
revealed a series of potential Sp1, AP-2, GCF and other bind-
ing sites (Fig. 3C). Since deletion of the promoter sequences to
nt 3222 had little e¡ect on promoter activity in the PLC/
PRF/5 cell line, we feel that the potential cis-elements up-
stream of this site are irrelevant for PRE activity in this par-
ticular cell line. However, the potential Sp1 sites located
downstream of nucleotide 3222 were of immediate interest.
We therefore performed EMSA using an oligonucleotide
spanning nt 3234 to nt 3215 (oligo A) to determine whether
Sp1 and/or Sp3 factors were present in the PLC/PRF/5 ex-
tracts, and interact with this sequence. The experiment re-
vealed four speci¢c DNA/protein complexes (Fig. 3D). Super-
shift assays using antibodies against Sp1 and Sp3 showed that
Fig. 4. Characterization of the Sp1/Sp3 site (CCTCC repeat) in the downstream HMG I-C promoter (nt 3473 to 331). A: Transfection analy-
sis of (top) the wild-type construct containing the I-C gene promoter region between nt 3289 to 331 fused to the luciferase gene, (middle) site-
directed mutant construct of region between nt 3232 to 3217 at the Sp1/Sp3 binding site, and (bottom) deletion mutant construct spanning re-
gion from nt 3217 to 331, transfected into PLC/PRF/5 cells. The right panel represents the percentage luciferase activity of each reporter con-
struct (as the mean with S.E.M. of at least three separate transfections from two independent plasmid preparation) relative to the wild-type
construct. B: Transfection analysis of the wild-type (WT) and the deletion mutant (deletant) constructs into Drosophila SL-2 cells, co-trans-
fected with Sp1 or Sp3 expression plasmids, shown as normalized luciferase activity. Data are the mean of at least three separate transfections
from two independent plasmid preparations.
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both Sp1 and Sp3 are indeed part of the shifted DNA/protein
complexes (Fig. 3D). No supershifted bands were observed
when an unrelated antibody (against NF-UB p65) was used
(data not shown). Similar experiments were repeated using a
point-mutated oligonucleotide (m-oligo A) carrying mutations
that alter both Sp1 and Sp3 consensus binding sites. As shown
in the second half of Fig. 3D, no supershifted complexes were
observed when using the mutated oligonucleotide.
3.5. De¢nition of the downstream HMG I-C PRE and its
transactivation by Sp1 and Sp3
Since the downstream PRE serves as a binding site for two
known transcriptional activating proteins (Sp1 and Sp3), we
tested the ability of reporter constructs which either lack this
site, or harbor a mutated version of the Sp1/Sp3 binding site,
to drive luciferase gene expression in PLC/PRF/5 cells (Fig.
4A). Deletion of the downstream PRE (to 3217) severely
abrogates promoter activity (10% of wild-type activity), and
mutagenesis of the PRE (with the mutant sequence being the
same as that used in m-oligo A in Fig. 3D) results in a 50%
inhibition of promoter activity (Fig. 4A). Taken together,
these data indicate that the downstream PRE is critical for
transcription from the downstream initiation site, and that the
Sp1/Sp3 sequence (likely in cooperation with unknown se-
quences downstream of 3289, but upstream of 3222) is an
important component of that promoter.
Since we had shown that the Sp1/Sp3 sequences are impor-
tant for transcription from the downstream PRE, and that
Sp1 and Sp3 proteins are components of nucleoprotein com-
plexes forming on these oligonucleotides, we next tested
whether the Sp1 and Sp3 proteins could transactivate this
promoter in Sp1/Sp3-de¢cient SL-2 cells. Fig. 4B shows that
while Sp1 and Sp3 can only weakly transactivate the wild-type
reporter construct that the two factors can cooperate to result
in maximal transcription. A reporter lacking the downstream
PRE is unresponsive to Sp1, Sp3, or Sp1 and Sp3.
4. Discussion
Cancers frequently arise from the inappropriate activation
of growth control genes either from translocation events or
from derepression of gene expression. Classic examples of
translocation-mediated gene activation/transformation are
the chromosome 8:14 translocation in B-cell lymphoma
(such that the immunoglobulin heavy chain enhancer drives
c-myc gene expression), and translocation into band 3q27
(BCL-6) in di¡use large-cell lymphoma [33,34]. The direct
role of inappropriate expression of oncogenes in cellular
transformation is well documented, especially in several trans-
genic mouse models of cancer [35^38]. Aberrant expression of
either full length or C-terminally truncated HMG I-C mRNA
is a frequent occurrence in neoplastic tissue [19,39^42]. This is
particularly true for benign tumors of mesenchymal origin,
but also has been observed in a variety of other benign and
malignant tumors [43]. Two biological phenomena suggest
that this aberrant expression might contribute to the trans-
formed phenotype. First, deletion of the HMG I-C gene re-
sults in a pygmy or runt phenotype, indicating that the HMG
I-C gene product is required for normal growth and develop-
ment [21]. Second, inhibition of HMG I-C gene expression via
expression of antisense HMG I-C mRNA arrests the in vitro
growth of thyroid tumor cell lines, and interferes with their
tumorigenicity in nude mice [22]. We have therefore begun to
probe molecular mechanisms driving HMG I-C gene expres-
sion in the hepatoma cell line PLC/PRF/5 with the aim of
understanding how this gene is reactivated in tumor tissue.
This study establishes that HMG I-C gene transcription
initiates from two major discrete sites within this hepatoma
cell line. The downstream initiation site reported in this study
is unique from that previously reported, and the promoter
elements driving this activity have therefore been character-
ized [33]. A single major transcription initiation site was
mapped by Chada’s group within the DLD-1 cell line [32].
This start is 118 bp 3P of the upstream start site mapped
our study (data not shown). Several minor extension products
were also reported observed in the DLD-1 line using two
primers. Thus, our current mapping of two major transcrip-
tion initiation sites in using PLC/PRF/5, along with Chada’s
previous mapping of multiple unrelated initiation sites in
DLD-1, extends the heterogeneity in initiation sites at this
upstream promoter. This is consistent with what is observed
in many TATAA-less promoters. The distinct initiation sites
in the two cell lines is interesting as it opens up the possibility
of cell-type speci¢c activation mechanisms.
While previous work has mapped transcription initiation
sites in the DLD-1 cell line, this work represents the ¢rst
analysis of cis-elements regulating transcription from any start
within the HMG I-C gene. The data presented here demon-
strate that transcription from each start site is controlled by
distinct positive regulatory elements. The upstream PRE is
located within nt 31125 to 31065 (data not shown), and
the downstream PRE within nt 3222 to 3217. Since our up-
stream start is near Chada’s start, we have elected to focus
our attention in this study on the novel downstream start site.
Sequence analysis of the downstream PRE indicates the
presence of multiple known cis-elements. Most notably, bind-
ing sites for AP-2, Sp1/Sp3 and GCF are clustered near the
functional PRE (Fig. 3C). Gel mobility shift experiments in-
dicate that both Sp1 and Sp3 (but not AP-2 ^ data not shown)
proteins interact with the downstream PRE (Fig. 3D). Inter-
estingly, distinct complexes in the EMSAs contained Sp1 and
Sp3, suggesting that distinct combinations of these factors
with other uncharacterized factors might mediate transcrip-
tion from this promoter. The existence of other nearby factors
(probably binding just upstream of the PRE) is supported by
the signi¢cant activity of the reporter construct harboring a
site-speci¢c mutation in the PRE (relative to the wild-type
3289 reporter), the dramatic a¡ect of deletion to 3217, and
the relatively weak transactivation of the reporters by Sp1 and
Sp3.
The data presented here suggest that activation of HMG I-
C expression in this hepatoma cell line is mediated by two
major PREs, which are distinct from those mapped in human
colorectal adenocarcinoma [32]. Thus, di¡erent molecular
pathways are likely to activate HMG I-C gene expression in
di¡erent tumor types. In support of this, we have recently
found that retinoblastomas initiate transcription from two
additional unique sites (K.-Y. Chau and S.J. Ono, unpub-
lished observations). Careful studies in various tumor cell
types and at di¡erent developmental stages will therefore be
required to properly understand HMG I-C gene regulation.
In the future we will focus on the biochemical puri¢cation
of additional DNA binding proteins interacting with the two
PREs, and their molecular cloning. The proteins interacting
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with the upstream PRE are completely unknown. The
CCGCCC consensus identi¢ed associated with both the up-
stream and downstream PREs are present in promoters of
several genes involving growth control like EGF receptor,
SV40 early, c-myc ([34] and references therein, Fig. 7) and
Ha-ras 1 [49]. The downstream PRE contains the character-
ized Sp1/Sp3 binding site with homology to the S1_HS sites
(5P-TCCTCCTCC-3P) found in the EGF receptor [34]. There-
fore, these are likely to be signi¢cant with respect to growth
control, and are of particular interest. It is known that Sp1
can interact with the sequence homologous to hypersensitive
sites and stimulate the in vitro transcription of templates con-
taining reiterated copies of this sequence [34,35], and it is
therefore signi¢cant that we have shown that both Sp1 and
Sp3 can interact with this site in PLC/PRF/5 cells.
It is also noteworthy that HMG I-C gene induction has
recently been shown to be dependent on the RAF-1/p44/p42
mitogen-activated protein kinase-dependent pathway in sali-
vary epithelial cells [44]. Additional future experiments will
investigate whether oncogenic Raf-1 can alter DNA/protein
interaction at either PRE identi¢ed in this study.
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